The pandemic provided a reason to the stock market to be excited about the pharma sector that had been facing lacklustre prospects amid challenges in the US business, USFDA compliance issues, pricing pressure, big-bang acquisitions not working out on expected lines and modest growth in the domestic market.
F&O Talk| Nifty’s narrow range breaks on Iran-Israel tensions; 24,450–24,500 emerges as key support: Sudeep Shah
Amidst escalating geopolitical tensions, Indian markets faced a downturn, with the Nifty and Sensex both declining. Analyst Sudeep Shah suggests a cautious approach, highlighting crucial
June 14, 2025